Cancer immunotherapy strategies including adoptive T-cell transfer (ACT) with Chimeric antigen receptor T-cell (CAR-T) or Tumor Infiltrating T-cell (TIL), cancer vaccine and immune checkpoint blockade with anti-CTLA4/anti-PD1 inhibitors have exhibited tremendous clinical power in cancer treatment (1–3). This evidence concerns the gene PDCD1 and cancer.